Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

KrKa DD

www.krka.si

Latest From KrKa DD

Krka Profits Leap On Double-Digit Sales Growth

Krka has enjoyed a 17% increase in operating profit on sales up by 12%, as the Slovenian company continues to reap the rewards of being among the European generic valsartan suppliers not to have been affected by widespread impurity-related recalls in 2018.

Sales & Earnings Strategy

Teva’s Ajovy & Pfizer’s Vizimpro Get EU Thumbs Up From CHMP

The European Medicines Agency’s drug evaluation committee has recommended for approval Teva’s Ajovy for migraine and Pfizer’s Vizimpro for NSCLC, as well as two more biosimilar versions of adalimumab (AbbVie’s Humira) and generics of atazanavir and feboxustat.

Approvals Europe

EU Servier Court Ruling 'Reduces Competition Law Risks For Pharma'

The EU’s General Court judgement in the Servier pay-for-delay case will put more pressure on competition authorities to show evidence of alleged abuse of a dominant position.

Scrip Asks… Is The Biosimilar Cost-Saving Theory Sustainable?

Scrip asks industry whether the promise of biosimilars producing substantial cost-savings is a sustainable model to help healthcare systems afford the next wave of expensive biologics. Drug developers and trade associations comment on the caveats still in play when it comes to biosimilars, cost-cutting and market access.

Biosimilars Market Access
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Eastern Europe
        • Slovenia
  • Parent & Subsidiaries
  • KrKa DD
  • Senior Management
  • Jose Colaric , Pres.
    Ales Rotar, Dir., R&D
  • Contact Info
  • KrKa DD
    Phone: (386) 7 331 21 11
    Smarjeska cesta 6
    Novo mesto , SI-8501
    Slovenia
Advertisement
Advertisement
UsernamePublicRestriction

Register